ESC Premium Access

Exploring the effects of SGLT2 inhibition in ongoing trials.

Topic: Diabetes and the Heart
Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Congress Presentation

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)
29 presentations
2 followers

5 more presentations in this session

Welcome and introduction - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

Evidence-based approaches to reducing premature cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease.

Speaker: Professor D. McGuire (Dallas, US)

Thumbnail

Applying evidence in practice: appropriate use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in the cardiology clinic.

Speaker: Doctor J. Udell (Toronto, CA) Professor N. Sattar (Glasgow, GB)

Thumbnail

Advancing the standard of care in patients with type 2 diabetes and established cardiovascular disease: how can we improve patient outcomes? .

Speaker: Professor N. Marx (Aachen, DE) Professor D. McGuire (Dallas, US) Doctor J. Udell (Toronto, CA) Professor S. Verma (Toronto, CA) Professor N. Sattar (Glasgow, GB)

Thumbnail

Summary and close - Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice.

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

Access the full session

Reducing cardiovascular mortality in patients with type 2 diabetes: closing the gap between evidence and practice

Speakers: Professor S. Verma, Professor N. Marx, Professor D. McGuire, Doctor J. Udell, Professor N. Sattar...
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb